INZY P/E Ratio
P/E Ratio as of Jun 13, 2025: -2.37
Average-2.36
Median-2.36
Minimum-2.37
Maximum-2.35
-2.37
Past Month-1.53 (182.14%)
The P/E ratio for INZY is -2.37 as of Jun 13, 2025. This represents a increase of 10.75% compared to its 12-month average P/E ratio of -2.14. A higher P/E ratio suggests that investors expect strong future earnings growth, while a lower P/E ratio may indicate a potentially undervalued stock or slowing growth.
Inozyme Pharma, Inc. P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Inozyme Pharma, Inc.’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Inozyme Pharma, Inc. to industry peers.
Inozyme Pharma, Inc. P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Inozyme Pharma, Inc.’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Inozyme Pharma, Inc. to industry peers.
INZY P/E Ratio Insights
See Inozyme Pharma, Inc.’s latest P/E ratio, historical trends, and valuation insights with AI-powered fundamental data and custom analysis.
Start investing in INZY
Order type
Buy in
Order amount
Est. shares
0 shares
INZY P/E Ratio Historic Data
| Date | Stock price | P/E ratio |
|---|---|---|
| Jun 2, 2025 | $3.975 | -2.36 |
| May 1, 2025 | $1.21 | -0.75 |
| Apr 1, 2025 | $0.87 | -0.54 |
| Mar 3, 2025 | $1.09 | -0.70 |
| Feb 3, 2025 | $1.38 | -0.89 |
| Jan 2, 2025 | $2.85 | -1.84 |
INZY End of Year P/E Ratio
| Date | P/E ratio | Change |
|---|---|---|
| 2025 | -2.37 | +32.40% |
| 2024 | -1.79 | -36.97% |
| 2023 | -2.84 | +517.39% |
| 2022 | -0.46 | -83.80% |
| 2021 | -2.84 | -66.78% |
| 2020 | -8.55 | — |
FAQs About Inozyme Pharma, Inc. (INZY) P/E ratio
The latest P/E ratio of INZY is -2.37, as of Jun 13, 2025. This is calculated based on its current stock price and earnings per share (EPS).
Inozyme Pharma, Inc.’s last 12-month average P/E ratio is -2.14, compared to its current P/E ratio of -2.37. This reflects a increase of 10.75%.
Inozyme Pharma, Inc.’s current P/E ratio of -2.37 is higher than its last 12-month average P/E of -2.14. A higher P/E can indicate strong future growth expectations, while a lower P/E might suggest undervaluation.
Inozyme Pharma, Inc.’s average P/E ratio over the last 3 years is -2.44. Comparing this to the current P/E helps assess recent valuation trends and whether the stock is trading above or below its mid-term historical range.
Inozyme Pharma, Inc.’s average P/E ratio over the last 5 years is -3.15. A deviation from this historical average may indicate shifts in growth expectations, profitability, or broader market conditions affecting valuation.